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Objectives: Human papillomavirus (HPV) infection is one of the most common sexually 
transmitted diseases. Long-term exposure to the HPV is a known cause of squamous 
intraepithelial lesions that consequently lead to cervical cancer development. The loop 
electrosurgical excision procedure (LEEP) conization is an established early cervical cancer 
treatment method. We aim to assess the remission of HPV infection after LEEP in non-
vaccinated patients with pre-cancerous cervical lesions and establish the efficacy of cervical 
cancer prophylaxis. 
Material and methods: We analyzed 31 LEEP conizations performed due to low and high-
grade squamous intraepithelial lesions in 2019–2020. We obtained molecular test samples and
detected DNA of 37 different HPV genotypes. After a six-month follow-up, each patient 
underwent subsequent high-risk HPV testing and genotyping. 
Results: We observed that 54.8% of qualified patients were infected with HPV 16. We 
discovered complete viral remission in 64.5% of cases. After surgery, margins were negative 
in 71% of the patient's samples. During the follow-up, six patients got infected with new 
strains of HPV. 
Conclusions: We found that a correctly performed LEEP conization may contribute to the 
remission of persistent HPV infection; a more extended follow-up period might be 
recommended due to a high rate of post-surgery HPV infections. 
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 INTRODUCTION
Cervical cancer remains the fourth most frequent cancer in women worldwide [1] despite 
the fact that this disease is theoretically wholly preventable. Persistent infection with high-risk
human papillomavirus is the direct cause of the majority of cervical intraepithelial neoplasia 
(CIN) and invasive cervical cancers. Vaccination against HPV prevents infections with 
specific HPV types and, consequently, the development of cervical cancer caused by the 
virus's specific strains [2–4]. We have been observing a decrease in cervical cancer incidence 
for several decades thanks to these preventive measures and screening.
Doctors and scientists have been searching years for diagnostic tools which show the 
highest sensitivity, specificity, and patients’ acceptance and allow to detect the disease at its 
earliest stage possible. These tools might be particularly useful in countries where cervical 
cancer incidence is still much higher than the world's average. An example of such a method 
is the optoelectronic method using a Truscreen. The procedure was convenient and had great 
potential for future use, especially in countries with limited access to colposcopy. However, 
despite this method's acceptable specificity, its sensitivity was significantly worse when 
compared to standard colposcopy and the HPV DNA test [5]. 
Early treatment of squamous intraepithelial lesions (SIL), especially high-grade (HSIL) is
considered the most crucial method of preventing cervical cancer. Cold knife conization, loop 
electrical excision procedure (LEEP), and large loop excision of the transformation zone 
(LLETZ) find themselves among other established treatment procedures
According to the Updated Consensus Guidelines for the Management of Abnormal 
Cervical Cancer Screening Tests and Cancer Precursors, both ablation and excision 
effectively treat CIN. Randomized trials comparing different modalities show similar efficacy,
ranging from 90% to 95% [6]. High-grade post-treatment disease may occur even in 18% of 
patients [7]; most recurrences are observed within two years post-treatment [8].
Previous studies reported that the incomplete excision of the endocervical cone margin 
during LEEP was a significant predictor for either persistence or recurrence of cervical 
intraepithelial neoplasia during follow-up [9, 10]. That is why the prolonged, careful 
observation of patients after surgical treatment may offer a significant chance to improve their
future prognosis. However, no recommendation specifies both time and methods of 
subsequent follow-up. When considering other procedures, HPV testing may offer adequate 
sensitivity for predicting recurrence, while HPV genotyping seems helpful in increasing the 
post-treatment predictive value [11].
The study aimed to access the molecular remission of HPV infection in patients after 
LEEP — conization who refused to be vaccinated against HPV. We carried out a retrospective
study to assess the ability of Pap-smear, HR-HPV testing, and their combination to identify 
residual or recurrent disease during the patients’ follow-up.
MATERIAL AND METHODS
This retrospective study included 31 patients with squamous intraepithelial neoplasia 
(SIL) treated with LEEP — conization between 2019 and 2020 at Provincial Hospital in 
Poznań. The LEEP — conization was performed in a total of 160 women; the only inclusion 
criterium for the study was the lack of consent for HPV vaccination. We obtained samples 
from all the patients for a Pap-smear and molecular test. The latter detected DNA of 37 
different HPV genotypes. After six months of follow-up, each woman underwent subsequent 
high-risk human papillomavirus testing and genotyping. All patients gave informed consent to
participate in the study. The research was approved by the Bioethics Committee of the 
Medical Chamber of Wielkopolska.
Pap-smear for molecular assessment was collected with the endocervical Cyto-Brush and 
preserved in PreservCyt® (Hologic Corp.) and SurePath® (BD Diagnostics-TriPath) reserved 
for the biological samples. The probe was handed over to the independent, standardized 
laboratory. HPV detection was performed using the PCR method, followed by DNA enzyme 
immunoassay and genotyping with a reverse hybridization line probe assay. Sequence 
analysis was performed to characterize HPV — positive samples with unknown HPV 
genotypes. The molecular test detected DNA of 37 different HPV genotypes.
Each colposcopy was performed by a specialist in gynecologic oncology with 10-year 
experience in SmartOPTIC colposcope. We performed a test with 5% aqueous solution of 
acetic acid and Schiller’s test with Lugol’s iodine in all included cases. The colposcopic 
images were evaluated according to Reid’s Colposcopic Index which assesses the color, lesion
boundaries and surface, blood vessels and result of the iodine test. All colposcopic images 
were archived. We used classification created by The International Federation of Cervical 
Pathology and Colposcopy, recommended by the Polish Society of Colposcopy and Cervical 
Pathophysiology.
The excisions were performed via the colposcope after application of acetic acid 5% and 
Lugol’s iodine. The sizes of the loops were selected according to the size of the lesion. When 
lesions reached high to the cervix, the lesion was excised deeper. We additionally sampled the
lesions’ margins. Finally, the curettage of the cervical canal was performed in order to obtain 
adequate endocervix samples. Between 12 to 16 paraffin blocks were prepared from each 
cervical specimen; each block was divided and examined in four to five sections. 
Histopathological analysis was performed in an independent laboratory by experienced 
pathologists. The follow-up schedule for all women included cytology and high-risk HPV 
genotyping at six months.  
Calculations were performed using the statistical package of Statistica (ver. 13.1), all 
graphs were created with Microsoft Excel. Statistical hypotheses were verified at the level of 
significance of p < 0.05. Fisher's exact test was used to analyze the relationship between 
persistent HPV infection after LEEP - conization and a positive margin. This specific test was 
chosen due to the expected small number of positive samples. A logistic regression model was




The mean age of women admitted for planned excision was 33 years. The vast majority 
of patients had less than three children, and more than a half lived in a town or a city with less
than 100,000 inhabitants. Table 1 presents descriptive characteristics of the study group. 
According to the Pap-smear results, one-third of hospitalized women were diagnosed with 
HSIL, one-third with LSIL, and 20% with atypical squamous cells (unable to exclude HSIL). 
We compiled all Pap-smear results in Figure 1. In total, 29 of 31 patients (93.5%) were 
positive for the HPV test before the surgery. In a group of 29 women with positive HPV test 
results, 17 cases (58.6%) tested positive for genotype 16. All the performed HPV test results 
and the occurrence of different genotypes are shown in Table 2.
According to the primary Pap-smear, HPV infection status, and colposcopy results, 25 
(80.6%) of women were pre-diagnosed with HSIL while five (16.1%) with LSIL. One patient 
had discrepancies in the results. According to the histopathological material acquired in the 
study, more than half of women had HSIL lesions, and about 32% of patients had no 
pathological changes in tested samples. Excised margins were fully clean in 22 women (71%) 
in both the ectocervix and cervical canal. A negative ectocervix margin was observed in 23 
patients (74.2%), while a negative cervical canal margin was found in 30 cases (96.7%). One 
patient presented a positive margin in the cervical canal despite having a negative margin in 
the ectocervix samples. Final histopathological results after LEEP-conization are presented in 
Figure 2. 
Follow-up
In the follow-up, we performed both Pap-smear and HPV genotyping tests. Pap-smear 
results were normal in 30 (96.7%) women. HPV genotyping tests showed viral remission in 
20 patients (64.5%), whereas in three cases (9%), the HPV infection was classified as 
persistent. One-third of negative Pap-smear cases were re-classified to persistent or recurrent 
HPV infection, based on their positive genotyping results. The persistent HPV infection was 
observed in three out of eight women with positive margins; however, the majority of these 
patients showed viral remission. Six patients (19.4%) had recurrent or persistent infection 
despite having a negative cervical margin. The relationship between the positive margin and 
persistent infection did not turn out to be statistically significant (p > 0.05). Seven patients 
tested positive for new HPV strains that hadn’t been detected before. The occurrence of 
positive margins and HPV infections after LEEP-conization is presented in Table 3. 
There was one Pap-smear positive for cancer cells, although the LEEP-conization 
results did not confirm the presence of any pathological changes. We also described one case 
with the preliminary cytological diagnosis of NILM (negative for intraepithelial lesion or 
malignancy), that was re-classified to HSIL after the performed histopathological 
examination. We assessed the correlation between age, HPV infection status, parity, and the 
final histological diagnosis — we found no statistically significant relationships (p > 0.05). 
DISCUSSION
This study assessed the molecular remission of HPV infection in patients after LEEP-
conization who refused vaccination against HPV. Active and effective treatment of HSIL is 
the primary approach to control the occurrence and development of cervical cancer. Cervical 
conization is one of the standardized treatments for HSIL. However, previous studies reported
that residual lesions and disease recurrence might occur frequently following this surgical 
procedure [12]. The positive margins after cervical conization are generally considered to be a
risk factor for the recurrence or persistence of SIL [13]. On the other hand, the viral clearance 
rate at the follow-up after conization is associated with negative excision margins, as 
confirmed by Cricca et al. [14]. In our study margins appeared to be clean in 22 (71%) 
women; the relationship between the positive margin and persistent infection did not turn out 
to be statistically significant. These divergent results might be caused by the insufficient size 
of the study group. 
We also investigated the ability of Pap-smear and HR-HPV testing to identify residual or 
recurrent disease during the patients’ follow-up. Despite the importance of early detection of 
treatment failure, follow-up after conservative treatment of high-grade CIN has not yet been 
standardized and varies in terms of timing, intervals, and methods. According to the ASCCP 
consensus guidelines, acceptable post-treatment management options for women with CIN 
2/3 include HPV DNA testing at 6 to 12 months. Follow-up with the use of Pap-smear alone 
or in combination with colposcopy at six months is also acceptable [21]. Several investigators 
analyzed the sensitivity and specificity of HPV DNA testing compared with Pap-smear to 
detect residual or recurrent disease after undergone treatment [22–24]. HPV testing was found
to be more sensitive than follow-up cytology, with comparable specificity of both mentioned 
methods [24, 25]. Women who are HPV-positive after surgery were statistically at higher risk 
for treatment failure [25, 27].
In research performed by Bruno et al., [26], 182 of 192 (94.7%) patients tested positive 
for HPV infection before the surgery. One hundred four women (57.1%) tested positive for 
genotype 16, 78 (42.8%) for other genotypes [26]. Our findings show a similar ratio — 93.5%
positive patients to 58.6% — cases positive for HPV 16 genotype. Women with pre-treatment 
HPV infections had higher incidence of post-treatment HPV presence compared to women 
who were HPV negative at or before treatment. Women who had been previously treated for 
cervical disorders may be more prone to develop subsequent cervical intraepithelial lesions or 
even cervical cancer than women without a history of cervical disease and treatment [16]. 
Although a substantial proportion of post-treatment dysplasia and cancers may result from an 
incomplete excision of the lesion, or the persistence of the lesion-associated HPV type, the 
affected patients are also at risk of developing a second cervical precancerous condition due to
the acquisition of newly acquired HPV strains. Data on type-specific HPV infections 
associated with a higher probability of cervical disease development after treatment are 
limited [17–20]. Most studies did not distinguish between recurrent or residual cervical 
disease, and most of them did not differentiate the newly acquired HPV-related lesions.
A finding beyond this study's scope confirmed that 9 of 31 women (29%) were still 
infected with HPV after surgical treatment. Interestingly, in seven of these cases the detected 
genotypes were new and not present in any previous samples. According to a review prepared 
by Anne F. Rositch et al., [15] most HPV incidence estimates were recorded among women 
treated for cervical neoplasia using LEEP. Presented data showed that the HPV incidence 
ranged from 0% to 18% at 2 to 6 months post-treatment and 0% to 24% at 6 to 35 months 
post-treatment [15]. Our results indicate that the rate of HPV infection after LEEP-conization 
(29%) is above the mentioned average. 
This study's limitations include its retrospective design and the fact that the entire 
research was conducted in a single medical facility. This fact may reduce the generalizability 
of our results to a broader geographic area. Further research with a prolonged follow-up 
period is highly recommended. 
CONCLUSIONS
A negative margin from the target lesion and a positive margin from the cervical canal 
may indicate that the changes may be located deeper, outside of the transformation zone. 
Therefore, it is important to remember that a simple Pap-smear test may not show the 
disease's full advancement and should not be treated as the only source of clinical decisions. A
more extended period of follow-up might be recommended due to a high rate of post-surgery 
HPV infections.  
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Table 1. Descriptive characteristics of the study group
Characteristics Category Value
Evaluated patients, n 31
Mean age at evaluation, 
years
33 
Area of residence, n (%)
 > 100.000 
inhabitants
13 (42)
 ≤ 100.000 
inhabitants
18 (58)
Thyroid disease, n (%)
Present 5 (16)
Absent 26 (84)
Parity, n (%) of children
0 14 (45.2)
1–2 13 (42)
≥ 3 4 (12.9)







Figure 1. Pap-smear results
Table 2. Occurrence of HPV genotypes within positive genotyping results.




16 17 (29.8) 1 (5.9)
58 4 (7) 1 (5.9)
73 4 (7) 1 (5.9)
31 3 (5.29) 0 (0)
33 3 (5.29) 0 (0)
45 3 (5.29) 2 (11.7)
53 3 (5.29) 2 (11.7)
66 3 (5.29) 1 (5.9)
6 2 (3.5) 0 (0)
11 2 (3.5) 0 (0)
51 2 (3.5) 1 (5.9)
54 2 (3.5) 1 (5.9)
18 1 (1.75) 0 (0)
35 1 (1.75) 0 (0)
52 1 (1.75) 0 (0)
56 1 (1.75) 1 (5.9)
59 1 (1.75) 2 (11.7)
61 1 (1.75) 0 (0)
62 1 (1.75) 0 (0)
68 1 (1.75) 1 (5.9)
82 1 (1.75) 1 (5.9)
90 0 (0) 1 (5.9)
70 0 (0) 1 (5.9)
† The patients could test positive for 1 or more HPV genotypes
1 A total number of HPV genotypes detected among 29 cases: 57 




Figure 2. Histopathological results after LEEP-conization





All cases 11 (35.5) 20 (64.5) 31 (100)
Ectocervix margin Positive 3 (37.5) 5 (62.5) 8 (100)
0.643
Negative 6 (26.1) 17 (73.9) 23 (100)
Cervical canal margin Positive 0 (0) 1 (100) 1 (100)
1.000
Negative 9 (30) 21 (70) 30 (100)
Data given as a number of cases (percent)     
